BRAF V600EPhase 3 (Cohort 3)ASCO GI 2026來源:人工整理
EC+FOLFIRI vs FOLFIRI±bev (1L)
關鍵結果ORR 64.4% vs 39.2%, OR 2.76; 肝 mets ORR 79.1%
FOLFIRI 也行——提供第二個化療骨幹選擇,特別適合 oxaliplatin 禁忌
詳細證據整理
BREAKWATER: Primary Analysis of First-Line (1L) Encorafenib + Cetuximab (EC) + FOLFIRI in BRAF V600E-Mutant mCRC
Study Design
- EC+FOLFIRI arm: n=73
- Control (FOLFIRI ± bevacizumab): n=74
Primary Endpoint: Objective Response Rate (ORR)
| Endpoint | EC+FOLFIRI | Control | Statistics |
|---|---|---|---|
| ORR (Primary) | 64.4% | 39.2% | OR 2.756, p=0.0011 |
| Complete Response (CR) | 4.1% | 1.4% | -- |
| Partial Response (PR) | 60.3% | 37.8% | -- |
Primary endpoint was met.
Secondary Endpoints
| Endpoint | EC+FOLFIRI | Control |
|---|---|---|
| Time to Response (TTR) | 6.9 weeks | 7.1 weeks |
| DOR ≥6 months | 57.4% | 34.5% |
| OS HR | 0.49 (95% CI: 0.237-1.032) -- trend favoring EC+FOLFIRI | |
Subgroup Analysis: Liver Metastases
| Subgroup | EC+FOLFIRI ORR | Control ORR | Odds Ratio |
|---|---|---|---|
| Patients with liver metastases | 79.1% | 37.0% | 6.44 |
Safety
The safety profile was consistent with the known profiles of each individual agent. No new safety signals were identified.
Conclusions
EC+FOLFIRI demonstrated a statistically significant improvement in ORR compared with FOLFIRI ± bevacizumab in first-line BRAF V600E-mutant mCRC. The results support EC + chemotherapy as a backbone for first-line treatment, with both mFOLFOX6 and FOLFIRI as viable chemotherapy partners.
本頁僅供醫療專業人員教育與臨床參考,不構成醫療建議;臨床決策請以原始文獻與現行指引為準。
讀者討論
讀者留言是個人意見,不是本站的文獻整理,也沒有經過醫學審核。
載入留言中…